Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methodichlorophen as anti-tumor drug.

L A Price, J H Goldie, B T Hill

    British Medical Journal
    |April 5, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Methodichlorophen demonstrated anti-tumor activity in patients with advanced cancers. This chemotherapy agent showed promise, particularly in lung cancer and hypernephroma, and can be safely administered orally to outpatients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

    Cell death & disease·2024
    Same author

    Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection.

    Bone marrow transplantation·2017
    Same author

    Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

    Bone marrow transplantation·2016
    Same author

    Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.

    Bone marrow transplantation·2016
    Same author

    Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

    Leukemia·2015
    Same journal

    Muscular pain during therapy with carbenoxolone (Biogastrone).

    British medical journal·2016
    Same journal

    ACUTE INTESTINAL OBSTRUCTION DUE TO INTRA-ABDOMINAL CAUSES.

    British medical journal·2014
    Same journal

    A CASE OF HAEMATIDROSIS.

    British medical journal·2014
    Same journal

    Incidence of ulcer in haematemesis.

    British medical journal·2011
    Same journal

    Pituitary hypothyroidism with impaired renal function.

    British medical journal·2011
    Same journal

    The fenestration operation for otosclerosis.

    British medical journal·2011
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Chemotherapy is a cornerstone in treating advanced malignant diseases.
    • Identifying novel therapeutic agents with manageable toxicity is crucial.

    Purpose of the Study:

    • To evaluate the efficacy and safety of Methodichlorophen in patients with terminal malignant disease.
    • To determine response rates in various cancer types.

    Main Methods:

    • Methodichlorophen was administered orally to 26 patients with advanced cancers.
    • Eight patients received adequate doses for efficacy assessment.
    • Tumor response was monitored objectively.

    Main Results:

    • Five out of eight patients receiving adequate doses showed objective tumor regression.

    Related Experiment Videos

  • Positive responses were observed in four of five lung cancer patients (squamous-cell and oat-cell carcinomas) and one hypernephroma patient.
  • Two testicular teratoma patients and one acute myeloid leukemia patient did not respond.

    • Conclusions:

    • Methodichlorophen exhibits anti-tumor activity in certain advanced malignancies.
    • The drug appears safe for oral outpatient administration with precautions.
    • Further investigation is warranted for specific cancer types like lung cancer.